Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit
=================================================================================================================

* Jason Langley
* Kristy S. Hwang
* Xiaoping P. Hu
* Daniel E. Huddleston

## Abstract

**Introduction** Striatal dopamine transporter imaging using 123I-ioflupane SPECT (DaTScan, GE) identifies 5-20% of newly diagnosed Parkinson’s disease (PD) subjects enrolling in clinical studies to have scans without evidence of dopaminergic deficit (SWEDD). These individuals meet diagnostic criteria for PD, but do not clinically progress as expected, and they are not believed to have neurodegenerative parkinsonism. Inclusion of SWEDD participants in PD biomarker studies or therapeutic trials may therefore cause them to fail. DaTScan can identify SWEDD individuals, but it is expensive and not widely available; an alternative imaging approach is needed. Here, we evaluate the use of neuromelanin-sensitive, iron-sensitive, and diffusion contrasts in substantia nigra pars compacta (SNpc) to differentiate SWEDD from PD individuals.

**Methods** Neuromelanin-sensitive, iron-sensitive, and diffusion imaging data for SWEDD, PD, and control subjects were downloaded from the Parkinson’s Progression Markers Initiative (PPMI) database. SNpc volume, SNpc iron (R2), and SNpc free water (FW) were measured for each participant.

**Results** Significantly smaller SNpc volume was seen in PD as compared to SWEDD (*P*<10−3) and control (*P*<10−3) subjects. SNpc FW was elevated in the PD group relative to controls (*P*=0.017). No group difference was observed in SNpc R2.

**Conclusion** In conclusion, nigral volume and FW in the SWEDD group were similar to that of controls, while a reduction in nigral volume and increased FW were observed in the PD group relative to SWEDD and control participants. These results suggest that these MRI measures should be explored as a cost-effective alternative to DaTScan for evaluation of the nigrostriatal system.

Keywords
*   neuromelanin
*   substantia nigra
*   SWEDD
*   Parkinson’s disease

## 1. Introduction

Neuronal loss in structures within the nigrostriatal system is a core feature of Parkinson’s disease (PD) [1, 2]. Much of this loss occurs in substantia nigra pars compacta (SNpc) during the prodromal stages of PD, and an estimated 30-50% of melanized neurons are lost by the time of symptom onset [2, 3]. Accordingly, efforts to develop neuroprotective therapies for PD increasingly focus on early-stage patients because the potential to prevent future neurodegeneration is greatest in this group. So far, no neuroprotective therapy has been established for PD at any stage [4], but early-stage PD patients have the most subtle features and can be especially challenging to diagnose. Thus, there is a pressing need for the development of imaging markers to assist selection of patients for recruitment into PD neuroprotection trials, particularly when these studies focus on early-stage PD patients. Imaging tools are also needed to monitor progression of neurodegeneration, and for development as surrogate outcome measures for these trials.

Striatal dopamine transporter imaging using 123I-ioflupane single photon positron emitted computed tomography (SPECT), also called DaTScan (GE Healthcare, Chicago, IL, USA), and 18F-fluorodopa positron emission tomography (PET) have found that between 5-20% of newly diagnosed PD subjects enrolling in clinical PD studies have scans without evidence of dopaminergic deficit (SWEDD) [5, 6]. Individuals with SWEDD meet clinical diagnostic criteria for PD but lack imaging evidence of nigrostriatal degeneration, the hallmark pathology of PD. A comparison of DaTScan images in a control participant, SWEDD participant, and PD participant is shown in Figure 1. Longitudinal study of SWEDD patients has found that they do not clinically progress significantly [7], and they are insensitive to treatment with levodopa [8]. Further, the highest percentage of SWEDD participants is observed in studies enrolling just after diagnosis [7, 9, 10]. While SWEDDs may be a heterogeneous group with a range of etiologies underlying their presentation with apparent clinical PD [5], they are unlikely to have idiopathic PD [7, 11] Therefore, inclusion of participants with SWEDD in biomarker studies or therapeutic trials for PD may cause them to fail due to inclusion of individuals without PD in the PD group.

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/10/30/2022.10.26.22281257/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257/F1)

Figure 1. 
A comparison of striatal binding ratio derived from DaTScan images at the level of the striatum in a control participant (left), SWEDD participant (middle), and PD participant (right).

DaTScan has been used in numerous clinical trials and biomarker studies to confirm the presence of neurodegenerative parkinsonism. However, limited availability, high cost, substantial time requirement (a 3-6 hour delay is needed between radionuclide injection and scan), and safety concerns relating to the use of radioisotopes impedes the widespread adoption of DaTScan [12]. The scan-rescan reproducibility of DaTScan is also sub-optimal for quantitative analysis of DaTScan as an outcome measure [13]. An MRI-based imaging marker to corroborate the presence of neurodegenerative parkinsonism in individuals meeting diagnostic criteria for PD could improve biomarker study and trial designs in terms of cost-effectiveness, safety, and availability, and it may improve the odds of success of PD clinical trials.

Neuromelanin-sensitive MRI can evaluate dopaminergic neurodegeneration in SNpc *in vivo* without ionizing radiation. Neuromelanin-sensitive MRI images with explicit or incidental magnetization transfer (MT) effects allow quantification of neuromelanin-associated contrast in SNpc [14, 15] and MT contrast has been shown to colocalize with melanized neurons [16, 17]. Application of MT effects to examine nigral depigmentation has revealed PD-related reductions in nigral volume [18, 19] or SNpc area in a single slice [20]. Neuromelanin-sensitive MRI methods have also been shown to have high scan-rescan reproducibility [21-23].

Histological studies have observed iron deposition alongside nigral depigmentation in PD [24, 25]. MR relaxometry measures the relaxation rate of the transverse magnetization (R2 or R2*) and is sensitive to iron [26]. Increases in transverse relaxation rate in the substantia nigra regions of interest defined in T2- or T2*-weighted images [27-31] or in regions of interest defined by neuromelanin-sensitive contrast [32-36] have been found. The regions of interest placed by neuromelanin-sensitive contrast are likely placed in the SNpc since neuromelanin-sensitive contrast colocalizes with melanized neurons [16].

Diffusion MRI is sensitive to the diffusivity of water, and it allows researchers to probe tissue microstructure. Tissue microstructural changes in the setting of neurodegeneration likely include a local increase in extracellular fluid due to both cell loss and vasogenic edema caused by a neuroinflammatory response [37]. Bi-compartment models applied to diffusion MRI data to separate restricted diffusion in intracellular compartments from extracellular fluid, i.e., the free water (FW) compartment, have also been applied to examine PD neurodegeneration-related changes in SNpc. Increases in nigral FW have been observed in PD patients as compared to controls [38-41]. In this study, we use a multi-contrast approach to examine the nigrostriatal system in PD and SWEDD. Specifically, DaTScan is used to stratify the PD and SWEDD groups and to examine striatal dopamine transporter (DAT) uptake, magnetization transfer effects are used to examine nigral volume, relaxometry is used to examine iron deposition, and a bi-compartment model is used to examine nigral microstructure in PD patients, controls, and individuals with SWEDD.

## 2. Methods

### 2.1 PPMI Overview

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database ([www.ppmi-info.org/data](http://www.ppmi-info.org/data)). For up-to-date information on the study, visit [www.ppmi-info.org](http://www.ppmi-info.org). Full inclusion and exclusion criteria for enrollment in PPMI can be found at [www.ppmi-info.org](http://www.ppmi-info.org). Institutional IRB approved the study for each site and subjects gave written informed consent.

### 2.2 Participants

Explicit MT effects are generated by the application of fat saturation pulses prior to excitation [15] and incidental MT effects are generated by interleaved turbo spin echo (TSE) acquisitions [42]. These effects can be used to generate neuromelanin-sensitive images and evaluate the loss of neuromelanin-sensitive contrast in SNpc. The PPMI database was queried for individuals with T1-weighted MP-RAGE acquisitions, dual echo TSE acquisitions with a fat saturation pulse, and cardiac-gated diffusion tensor imaging (DTI) acquisitions.

Criteria for inclusion of subjects from the PPMI database used in this analysis were as follows: 1) participants must be scanned with cardiac-gated diffusion tensor imaging (DTI) and dual echo turbo-spin echo (TSE) with a fat saturation pulse and 2) participants must have DTI and TSE scans with scan parameters matching those in the PPMI imaging protocol. The 24-month time point was chosen for evaluation in the PD group since that time point contains the largest number of subjects with TSE acquisitions with a fat saturation pulse. A total of 163 subjects (33 controls (CO), 33 SWEDD, 97 PD patients) met these criteria. All PD and SWEDD subjects underwent DaTScan to confirm diagnosis. Imaging data were downloaded in December 2019.

### 2.3 MRI Acquisition

All MRI data used in this analysis were acquired on Siemens scanners. T1-weighted structural images in the PPMI cohort were used for registration to common space. Dual echo TSE images were acquired with the following parameters: TE1/TE2/TR=11/101/3270 ms, FOV=240×213 mm2, voxel size=0.9×0.9×3 mm3, fat saturation pulse, 48 slices. The first echo of the TSE acquisition contains magnetization transfer effects from the fat saturation pulse and interleaved TSE acquisition. Cardiac-gated diffusion-MRI data in the PPMI cohort were acquired using a monopolar diffusion encoding gradient with 64 unique gradient directions and the following parameters: TE/TR=88/650-1100 ms, flip angle=90°, FOV=229×229 mm2, voxel size=1.98×1.98×2 mm3, *b*=1000 s/mm2, cardiac-triggered, with 72 slices.

### 2.4 Image Processing

Diffusion data was preprocessed with FSL [43]. Diffusion MR data were corrected for motion and eddy-current distortions using EDDY in FSL. Next, susceptibility distortions were reduced by nonlinearly fitting the *b*=0 image to second echo from the TSE acquisition. Parameters derived from the diffusion data were estimated using DTIFIT in FSL. A bi-compartment model, as implemented in DIPY [44], was used to calculate free water images. Next, the *b*=0 image was brain extracted and registered to the brain extracted T1-weighted image using a rigid body transform with a boundary-based registration cost function.

*R*2, an MRI measure sensitive to iron, was calculated from the dual echo TSE acquisition using a custom script in MATLAB by fitting a monoexponential model to the dual echo TSE images. For each voxel, R2 was calculated from the dual echo TSE acquisition using the following equation: ![Formula][1]</img>  where *S*(*TE**i*) denotes the signal at echo time *TE*i. The resulting *R*2 maps were aligned to the T1-weighted image using a rigid body transform derived via the magnitude image from the first echo.

### 2.5 Regions of Interest

An SNpc atlas, derived from magnetization-transfer images in a cohort of 76 healthy older participants (aged 66 years ± 6 years), was used as a region of interest (ROI) in the diffusion analysis [45]. The SNpc atlas was transformed from MNI space to subject space using linear and nonlinear transforms in FSL as previously described [46]. The SNpc atlas was thresholded at 60%, representing 60% of the population, and binarized. Mean FW and R2 was calculated in the SNpc for each subject.

SNpc was segmented using a thresholding method. A reference region was drawn in the cerebral peduncle in MNI common space and then transformed to individual NM-MRI images and used to threshold. Thresholding was restricted to the anatomic location of SNpc using the probabilistic standard space mask [45]. Voxels with intensity >μref+3σref were considered part of SNpc.

### 2.6 Statistical Analysis

All statistical analyses were performed using IBM SPSS Statistics software version 24 (IBM Corporation, Somers, NY, USA) and results are reported as mean ± standard error. A *P* value of 0.05 was considered significant for all statistical tests performed in this work. A chi-squared test was used to evaluate gender differences in group. Normality of SNpc volumes and diffusion metrics was assessed using the Shapiro-Wilk test for each group and all data was found to be normal. The effect of group (SWEDD, PD, control) was tested with separate analysis of variance (ANOVA) for SNpc volume, mean SNpc FW, and mean SNpc R2. Since iron correlates with single-compartment diffusion indices, mean diffusivity and fractional anisotropy, were not used in this analysis [46]. ANOVA was used to test the effect of group (SWEDD, PD, control) on the ratio of caudate nucleus striatal binding ratio (SBR) to the putamen SBR. Caudate and putamen SBRs were obtained from summary variables in the PPMI database. For all ANOVAs, if the interaction was significant, post hoc comparisons between each pair of groups were performed using respective two-tailed t-tests. Correlations between SNpc volume, mean SNpc FW, and mean SNpc R2 and clinical measures (UPDRS and disease duration) were assessed in the PD and SWEDD groups. A correlation was considered significant if *P*<0.05 after multiple comparison correction. To test the feasibility of using MRI metrics to differentiate SWEDD from PD, receiver operator characteristic (ROC) curves were obtained for SNpc volume SNpc FW, and SNpc *R*2 values.

## 3. Results

### 3.1 Participants

Demographic data for each group is shown in Table 1. The ANOVA found no significant group effect in participant age (*P*=0.860; *F*=0.151), and education (*P*=0.322; *F*=1.41). No difference in gender was observed between PD and control groups (*P*=0.184), PD and SWEDD groups (*P=*0.747), and SWEDD and control groups (*P*=0.174). A significant group effect was seen in MoCA (*P*=0.042; *F*=3.218). The CO group had a higher MoCA score as compared to the SWEDD (*P=*0.019) and PD (*P*=0.034) groups. No difference was seen in MoCA between SWEDD and PD groups (*P*=0.439). A significant group effect was seen in UPDRS-III ON score (*P*<10−4; *F*=45.506) with the PD group having a higher UPDRS-III ON score than the CO (*P*<10−4) and SWEDD (*P*<10−4) groups. The SWEDD group had a higher UPDRS-III ON score as compared to the CO group (*P=*0.003).

View this table:
[Table 1.](http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257/T1)

Table 1. 
Demographic information for the groups used in this analysis. Data is presented as mean ± standard error. One-way ANOVAs were used for group comparisons of age, education, cognition, UPDRS-III ON medication score, and CSF *α*-synuclein from which *P* values are shown. A chi-squared test was used to assess group differences in gender.

### 3.2 Effects of Group

A comparison of SNpc contrast in the first echo from the TSE acquisition for control, SWEDD, and PD subjects is shown in Figure 2. The effect of group (PD, SWEDD, control) was tested with ANOVAs in each MRI measure (SNpc volume, SNpc R2, free water). A significant main effect in group (*P*<10−4; *F=*33.475) was seen for SNpc volume. Pairwise-comparisons of means showed decreases in SNpc volume in the PD group (PD: 308 mm3 ± 14 mm3) relative to the control group (CO: 483 mm3 ± 24 mm3; *P*<10−3) and SWEDD (SWEDD: 493 mm3 ± 24 mm3; *P*<10−3) groups. No difference was seen in SNpc volume between SWEDD and control groups (*p*=0.235). No significant main effect was found in SNpc R2 (*P*=0.564; *F=*0.570). A significant main effect in group was seen in SNpc free water (*p*=0.027; *F=*3.710) with group means showing increases in SNpc free water in the PD group (PD: 0.198 ± 0.006) relative to control group (CO: 0.169 ± 0.010; *P*=0.017), and a non-significant trend toward increased SNpc FW in PD vs. SWEDD (SWEDD: 0.177 ± 0.010; *P*=0.074) was observed. No difference was seen in SNpc free water between the SWEDD and control (*P*=0.579) groups. Group comparisons are shown in Figure 3.

![Figure 2.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/10/30/2022.10.26.22281257/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257/F2)

Figure 2. 
A comparison of neuromelanin-sensitive contrast from the first echo of the TSE acquisition in controls (left panel), PD (middle panel), and SWEDD (right panel) subjects. The PD subject exhibits a loss of contrast as compared to the control and SWEDD subjects

![Figure 3.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/10/30/2022.10.26.22281257/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2022/10/30/2022.10.26.22281257/F3)

Figure 3. 
Group comparisons for SNpc volume (A), SNpc FW (B), SNpc R2 (C), left DaT striatal uptake ratio (D), and right DaT striatal uptake ratio (E) in control, SWEDD, and PD groups. AUC curves for SNpc volume, mean SNpc FW, and mean SNpc R2 are shown in (F). SNpc volume outperformed mean SNpc FW and mean SNpc R2 as a diagnostic marker to differentiate SWEDD from PD. All box plots, the top and bottom of the box denote the 25th and 75th percentiles, respectively, with the line denoting the median value. In (A-F), * denotes *P*<0.05 and ** denotes *P*<0.01.

Using the DaTScan data, the effect of group (PD, SWEDD, control) was tested with ANOVAs on striatal binding ratios (SBRs), i.e. the ratio of striatal uptake to occipital uptake. Specifically, the ratio of caudate nucleus SBR to putamen SBR was determined for each participant, and a significant main effect between groups was observed for the left (*F=*68.585, *P*<10−3) and right (*F*=41.538, *P*<10−3) ratios. Pairwise-comparisons of means showed increases in the ratio of caudate SBR to putamen SBR in the PD group (left: 2.7 ± 0.8; right: 2.7 ± 1.0) relative to control group (left: 1.5 ± 0.2; right: 1.3 ± 0.2) as well as relative to the SWEDD group (left: 1.4 ± 0.4; right: 1.5 ± 0.4) on both left and right sides (*Ps*<10−3). No difference was seen in the ratio of caudate SBR to putamen SBR between control and SWEDD groups (left: *P*=0.819; right: *P*=0.496).

### 3.2 Clinical Correlations

No significant correlations were observed between any MRI measure (SNpc volume, SNpc FW, or SNpc R2) and any clinical measure (UPDRS-III and disease duration) in the PD group (*Ps*>0.267) or in the SWEDD group (*Ps*>0.179).

### 3.2 ROC Analysis

SNpc volume differentiated SWEDD from PD better than SNpc FW or SNpc R2. The area under the ROC curve (AUC) for SNpc volume was 0.786 (standard error (SE)=0.048; 95% confidence interval (CI): 0.692–0.880; *P*<10−4). The AUC for mean SNpc FW was 0.489 (SE=0.060; 95% CI: 0.371–0.607; *P*=0.861) while the AUC for mean SNpc R2 was 0.405 (SE=0.060; 95% CI: 0.272–0.539; *P*=0.163). AUC curves are shown in **Figure 3**.

## 4. Discussion

Participants with SWEDD are individuals who have clinical features of parkinsonism and meet diagnostic criteria for PD, but they do not exhibit presynaptic dopaminergic deficits on DaTScan (see Figure 1). To date, the underlying pathophysiology in patients with clinical features of parkinsonism and SWEDD remains controversial. However, these individuals typically do not progress clinically or radiographically as expected in neurodegenerative parkinsonism [7], and they appear to represent a heterogeneous group that does not have idiopathic PD [11]. Currently, DaTScan is used as a screening tool to exclude SWEDDs in clinical PD studies. In research studies enrolling PD patients within 9 months of diagnosis approximately 5-20% of participants will be SWEDD, with the highest percentage occurring in studies recruiting newly diagnosed PD [7, 9, 10]. However, lack of availability of DaTScan, high cost, and exposure to ionizing radiation from the radioligand limit its use. Thus, there is a need for a widely available screening tool to exclude SWEDDs from enrollment in PD clinical studies, because these individuals are unlikely to have neurodegenerative parkinsonism [7]. This study examines the performance of nigral MRI metrics to differentiate SWEDD from PD. We found that nigral MRI metrics (SNpc volume, SNpc FW) in the SWEDD group resemble those derived in the control group and differ from PD.

The radiotracer used in DaTScan binds to dopamine transporter (DAT) in the presynaptic membrane of dopamine neuron axon terminals and is sensitive to the loss of membrane DAT protein, axonal neuronal loss, or nigrostriatal neuronal loss [47]. SWEDD patients do not show deficits in striatal DAT uptake, and our analysis of caudate nucleus to putamen SBR found results that were consistent with this. This is an expected result, since the PD and SWEDD groups are stratified based on their DaTScan results, but it is a useful confirmation of the basis of this study design. Neuromelanin-sensitive contrast is correlated with DAT binding [48, 49] and co-localizes with pigmented catecholamine neurons [16]. These results imply that SNpc should not undergo neurodegeneration in SWEDD. In agreement with this, no difference was observed in nigral FW and nigral volume between SWEDD and control groups.

In contrast to the SWEDD group, a reduction in SNpc volume was observed in the PD group relative to the control group. This result is in agreement with earlier studies that found nigral volume is reduced in PD patients [18, 19] or contrast is reduced in the lateral and ventral portion of SNpc [50]. The reduction in volume may be caused by depletion of melanized neurons in nigrosome-1, the subregion of SNpc that undergoes the greatest loss neuronal loss [1], as earlier studies have noted reductions in neuromelanin-sensitive contrast in regions consistent with nigrosome 1[15, 45]. Increases in nigral FW were also seen in the PD group relative to the control group, which is consistent with other studies reporting nigral FW increases in PD [39, 41].

When comparing SWEDD and PD, nigral volume outperformed nigral FW and nigral R2 as a diagnostic marker. These findings suggest that nigral volume, or other nigrostriatal imaging measures, could be useful for removal of SWEDDs in clinical trials. While the SNpc volume discrimination of PD vs. SWEDD approaches a useful level for clinical trial participant selection with an AUC of 0.786 (AUC > 0.8 is a typically discussed threshold), further improvements in accuracy are needed to make clinical decisions at the individual level, which would require AUC > 0.9. Diagnostic accuracy may be improved by using neuromelanin-sensitive acquisitions based on explicit magnetization transfer effects [22, 23] or incorporating other metrics, such as UPDRS score or MRI metrics from other structures, in machine learning classification algorithms. Metrics derived from neuromelanin-sensitive data show promise for differential diagnosis of parkinsonian syndromes [51-53] and further development of these metrics may allow for accurate discrimination of SWEDD from PD.

This study has several caveats. First, R2, a measure derived from a multiecho TSE sequence, was used to measure nigral iron deposition in PD and SWEDD. R2 is not as sensitive to iron deposition as R2* or susceptibility, which are derived from gradient-echo acquisitions, [26]. Further, R2* has been shown to be a robust marker for examining nigral iron deposition in PD [33] and may aid in differentiating SWEDD from PD. Second, incidental magnetization transfer effects from an interleaved multislice turbo spin echo acquisition were used to generate contrast sensitive to neuromelanin. Neuromelanin-sensitive MRI approaches employing explicit magnetization transfer effects exhibit high scan-rescan reproducibility in controls, outperforming methods based on incidental magnetization transfer effects [22, 23]. The use of explicit magnetization transfer effects may improve diagnostic accuracy for differentiating SWEDD from PD. Finally, no correlations were observed between MRI measures (nigral R2, nigral FW, nigral volume) and clinical features (disease duration, UPDRS-III score). The lack of correlation may also be explained in part by insensitivity of the imaging measures (incidental magnetization transfer effects and R2). However, since the PD subjects in PPMI are recruited at the time of initial diagnosis and therefore have very similar disease duration and clinical states (e.g., similar UPDRS-III scores), the lack of correlation may be due to insufficient variation in the clinical variables.

In conclusion, nigral volume and nigral FW in the SWEDD group were similar to that of the control group while a reduction in nigral volume and an increase in FW were observed in the PD group relative to the SWEDD and control groups. The changes in nigral volume and FW in the PD group are consistent with SNpc neurodegeneration effects in PD. With further development, nigral volume and FW may become markers used for differential diagnosis of SWEDD from PD. These imaging markers may be used to exclude individuals with SWEDD from PD neuroprotection trials.

## Data Availability

All data supporting these analyses are available through the Parkinson's Progression Markers Initiative (PPMI) database ([www.ppmi-info.org/data](https://www.ppmi-info.org/data)).

## Acknowledgements

PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including [list the full names of all of the PPMI funding partners found at [www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors](http://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors)].

This work is supported by the NIH-NINDS 1K23NS105944-01A1 (Huddleston), NIH-NIA 1U19AG071754-01 (Huddleston, Hu, Langley), the Department of Veteran Affairs 1I01RX002967-01A2 (Huddleston), the Emory American Parkinson’s Disease Association Center for Advanced Research (Huddleston), the Emory Lewy Body Dementia Association Research Center of Excellence (Huddleston), and the Michael J Fox Foundation (MJF-10854, MJFF-010556; Huddleston, Hu, Langley).

*   Received October 26, 2022.
*   Revision received October 26, 2022.
*   Accepted October 30, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at [http://creativecommons.org/licenses/by-nd/4.0/](http://creativecommons.org/licenses/by-nd/4.0/)

## References

1.  [1]. P. Damier,  E.C. Hirsch,  Y. Agid,  A.M. Graybiel, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease, Brain 122 (Pt 8) (1999) 1437–48.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/122.8.1437&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=10430830&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000082259700004&link_type=ISI) 

2.  [2]. J.M. Fearnley,  A.J. Lees, Ageing and Parkinson’s disease: substantia nigra regional selectivity, Brain 114 (Pt 5) (1991) 2283–301.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/114.5.2283&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=1933245&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1991GR31100017&link_type=ISI) 

3.  [3]. H.-C. Cheng,  C.M. Ulane,  R.E. Burke, Clinical progression in Parkinson disease and the neurobiology of axons, Annals of Neurology 67(6) (2010) 715–725.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ana.21995&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20517933&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000278208400006&link_type=ISI) 

4.  [4]. D. Athauda,  T. Foltynie, The ongoing pursuit of neuroprotective therapies in Parkinson disease, Nat Rev Neurol 11(1) (2015) 25–40.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nrneurol.2014.226&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25447485&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

5.  [5]. R. Erro,  S.A. Schneider,  M. Stamelou,  N.P. Quinn,  K.P. Bhatia, What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies, J Neurol Neurosurg Psychiatry 87(3) (2016) 319–23.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiam5ucCI7czo1OiJyZXNpZCI7czo4OiI4Ny8zLzMxOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzEwLzMwLzIwMjIuMTAuMjYuMjIyODEyNTcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

6.  [6]. A. Batla,  R. Erro,  M. Stamelou,  S.A. Schneider,  P. Schwingenschuh,  C. Ganos,  K.P. Bhatia, Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study, Mov Disord 29(14) (2014) 1820–5.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mds.26018&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25350529&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

7.  [7]. K. Marek,  J. Seibyl,  S. Eberly,  D. Oakes,  I. Shoulson,  A.E. Lang,  C. Hyson,  D. Jennings,  P.I. Parkinson Study Group, Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, Neurology 82(20) (2014) 1791–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/WNL.0000000000000424&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24759846&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

8.  [8]. S. Fahn,  G. Parkinson Study, Does levodopa slow or hasten the rate of progression of Parkinson’s disease?, J Neurol 252 Suppl 4 (2005) IV37–IV42.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00415-005-4008-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16222436&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

9.  [9]. S. Fahn,  D. Oakes,  I. Shoulson,  K. Kieburtz,  A. Rudolph,  A. Lang,  C.W. Olanow,  C. Tanner,  K. Marek,  G. Parkinson Study, Levodopa and the progression of Parkinson’s disease, The New England journal of medicine 351(24) (2004) 2498–508.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa033447&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15590952&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000225593100005&link_type=ISI) 

10. [10]. G. Parkinson Study, Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression, JAMA 287(13) (2002) 1653–61.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.287.13.1653&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11926889&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000174730300019&link_type=ISI) 

11. [11]. J.W. Lee,  Y.S. Song,  H. Kim,  B.D. Ku,  W.W. Lee, Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson’s disease: Analysis of the PPMI data, PLoS One 16(2) (2021) e0246881.
    
    

12. [12]. R. de la Fuente-Fernandez, Is DaTSCAN really needed for accurate Parkinson’s disease diagnosis?, Expert Rev Neurother 12(12) (2012) 1375–7.
    
    

13. [13]. S. Bhattacharjee,  V. Paramanandam,  A. Bhattacharya, Analysis of the Effect of Dopamine Transporter Scan on the Diagnosis and Management in a Tertiary Neurology Center, Neurohospitalist 9(3) (2019) 144–150.
    
    

14. [14]. X. Chen,  D.E. Huddleston,  J. Langley,  S. Ahn,  C.J. Barnum,  S.A. Factor,  A.I. Levey,  X. Hu, Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach, Magn Reson Imaging 32(10) (2014) 1301–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.mri.2014.07.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

15. [15]. S.T. Schwarz,  T. Rittman,  V. Gontu,  P.S. Morgan,  N. Bajaj,  D.P. Auer, T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease, Mov Disord 26(9) (2011) 1633–38.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mds.23722&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21491489&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

16. [16]. S. Kitao,  E. Matsusue,  S. Fujii,  F. Miyoshi,  T. Kaminou,  S. Kato,  H. Ito,  T. Ogawa, Correlation between pathology and neuromelanin MR imaging in Parkinson’s disease and dementia with Lewy bodies, Neuroradiology 55(8) (2013) 947–53.
    
    

17. [17]. N.I. Keren,  S. Taheri,  E.M. Vazey,  P.S. Morgan,  A.C. Granholm,  G.S. Aston-Jones,  M.A. Eckert, Histologic validation of locus coeruleus MRI contrast in post-mortem tissue, Neuroimage 113 (2015) 235–45.
    
    

18. [18]. G. Castellanos,  M.A. Fernandez-Seara,  O. Lorenzo-Betancor,  S. Ortega-Cubero,  M. Puigvert,  J. Uranga,  M. Vidorreta,  J. Irigoyen,  E. Lorenzo,  A. Munoz-Barrutia,  C. Ortiz-de-Solorzano,  P. Pastor,  M.A. Pastor, Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson’s Disease, Mov Disord 30(7) (2015) 945–952.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mds.26201&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25772492&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

19. [19]. K. Ogisu,  K. Kudo,  M. Sasaki,  K. Sakushima,  I. Yabe,  H. Sasaki,  S. Terae,  M. Nakanishi,  H. Shirato, 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease, Neuroradiology 55(6) (2013) 719–724.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00234-013-1171-8&link_type=DOI) 

20. [20]. S. Reimao,  P. Pita Lobo,  D. Neutel,  L. Correia Guedes,  M. Coelho,  M.M. Rosa,  J. Ferreira,  D. Abreu,  N. Goncalves,  C. Morgado,  R.G. Nunes,  J. Campos,  J.J. Ferreira, Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson’s disease patients, Eur J Neurol 22(3) (2015) 540–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/ene.12613&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25534480&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

21. [21]. J. Langley,  D.E. Huddleston,  C.J. Liu,  X. Hu, Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI, MAGMA 30(2) (2017) 121–125.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10334-016-0590-z&link_type=DOI) 

22. [22]. K. Wengler,  X. He,  A. Abi-Dargham,  G. Horga, Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses, Neuroimage 208 (2020) 116457.
    
    

23. [23]. M. van der Pluijm,  C. Cassidy,  M. Zandstra,  E. Wallert,  K. de Bruin,  J. Booij,  L. de Haan,  G. Horga,  E. van de Giessen, Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences, J Magn Reson Imaging 53(3) (2021) 712–721.
    
    

24. [24]. D.T. Dexter,  F.R. Wells,  F. Agid,  Y. Agid,  A.J. Lees,  P. Jenner,  C.D. Marsden, Increased nigral iron content in postmortem parkinsonian brain, Lancet 2(8569) (1987) 1219–20.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(87)91361-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=2890848&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1987K889500058&link_type=ISI) 

25. [25]. F.A. Zucca,  J. Segura-Aguilar,  E. Ferrari,  P. Munoz,  I. Paris,  D. Sulzer,  T. Sarna,  L. Casella,  L. Zecca, Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease, Progress in neurobiology 155 (2017) 96–119.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.pneurobio.2015.09.012&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26455458&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

26. [26]. C. Langkammer,  N. Krebs,  W. Goessler,  E. Scheurer,  F. Ebner,  K. Yen,  F. Fazekas,  S. Ropele, Quantitative MR imaging of brain iron: a postmortem validation study, Radiology 257(2) (2010) 455–62.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1148/radiol.10100495&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20843991&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000283187800023&link_type=ISI) 

27. [27]. S. Baudrexel,  L. Nurnberger,  U. Rub,  C. Seifried,  J.C. Klein,  T. Deller,  H. Steinmetz,  R. Deichmann,  R. Hilker, Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease, Neuroimage 51(2) (2010) 512–20.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuroimage.2010.03.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20211271&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

28. [28]. G. Du,  M.M. Lewis,  M. Styner,  M.L. Shaffer,  S. Sen,  Q.X. Yang,  X. Huang, Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson’s disease, Mov Disord 26(9) (2011) 1627–32.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/mds.23643&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21618607&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

29. [29]. P. Kosta,  M.I. Argyropoulou,  S. Markoula,  S. Konitsiotis, MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease, J Neurol 253(1) (2006) 26–32.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00415-005-0914-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15981079&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000234949400005&link_type=ISI) 

30. [30]. W.R. Martin,  M. Wieler,  M. Gee, Midbrain iron content in early Parkinson disease: a potential biomarker of disease status, Neurology 70(16 Pt 2) (2008) 1411–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1212/01.wnl.0000286384.31050.b5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18172063&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

31. [31]. P. Peran,  A. Cherubini,  F. Assogna,  F. Piras,  C. Quattrocchi,  A. Peppe,  P. Celsis,  O. Rascol,  J.F. Demonet,  A. Stefani,  M. Pierantozzi,  F.E. Pontieri,  C. Caltagirone,  G. Spalletta,  U. Sabatini, Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature, Brain 133(11) (2010) 3423–33.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/awq212&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20736190&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000283666500029&link_type=ISI) 

32. [32]. N. He,  J. Langley,  D.E. Huddleston,  S. Chen,  P. Huang,  H. Ling,  F. Yan,  X. Hu, Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson’s disease, Neuroimage Clin 28 (2020) 102391.
    
    

33. [33]. J. Langley,  N. He,  D.E. Huddleston,  S. Chen,  F. Yan,  B. Crosson,  S. Factor,  X. Hu, Reproducible detection of nigral iron deposition in 2 Parkinson’s disease cohorts, Mov Disord 34(3) (2019) 416–419.
    
    

34. [34]. Z. Jin,  Y. Wang,  M. Jokar,  Y. Li,  Z. Cheng,  Y. Liu,  R. Tang,  X. Shi,  Y. Zhang,  J. Min,  F. Liu,  N. He,  F. Yan,  E.M. Haacke, Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template, Hum Brain Mapp 43(6) (2022) 2011–2025.
    
    

35. [35]. N. He,  K. Ghassaban,  P. Huang,  M. Jokar,  Y. Wang,  Z. Cheng,  Z. Jin,  Y. Li,  S.K. Sethi,  Y. He,  Y. Chen,  S. Gharabaghi,  S. Chen,  F. Yan,  E.M. Haacke, Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson’s disease, Neuroimage 230 (2021) 117810.
    
    

36. [36]. J. Langley,  D.E. Huddleston,  J. Sedlacik,  K. Boelmans,  X.P. Hu, Parkinson’s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta, Mov Disord 32(3) (2017) 441–449.
    
    

37. [37]. M. Febo,  P.D. Perez,  C. Ceballos-Diaz,  L.M. Colon-Perez,  H. Zeng,  E. Ofori,  T.E. Golde,  D.E. Vaillancourt,  P. Chakrabarty, Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-gamma, Brain Struct Funct 225(1) (2020) 427–439.
    
    

38. [38]. T. Guttuso, Jr..,  N. Bergsland,  J. Hagemeier,  D.G. Lichter,  O. Pasternak,  R. Zivadinov, Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease, AJNR Am J Neuroradiol 39(3) (2018) 479–484.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpuciI7czo1OiJyZXNpZCI7czo4OiIzOS8zLzQ3OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzEwLzMwLzIwMjIuMTAuMjYuMjIyODEyNTcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

39. [39]. E. Ofori,  O. Pasternak,  P.J. Planetta,  R. Burciu,  A. Snyder,  M. Febo,  T.E. Golde,  M.S. Okun,  D.E. Vaillancourt, Increased free water in the substantia nigra of Parkinson’s disease: a single-site and multi-site study, Neurobiol Aging 36(2) (2015) 1097–104.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neurobiolaging.2014.10.029&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25467638&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

40. [40]. R.G. Burciu,  E. Ofori,  D.B. Archer,  S.S. Wu,  O. Pasternak,  N.R. McFarland,  M.S. Okun,  D.E. Vaillancourt, Progression marker of Parkinson’s disease: a 4-year multi-site imaging study, Brain 140(8) (2017) 2183–2192.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/brain/awx146&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28899020&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

41. [41]. J. Langley,  D.E. Huddleston,  X. Hu, Nigral diffusivity, but not free water, correlates with iron content in Parkinson’s disease, Brain Commun 3(4) (2021) fcab251.
    
    

42. [42]. W.T. Dixon,  H. Engels,  M. Castillo,  M. Sardashti, Incidental magnetization transfer contrast in standard multislice imaging, Magn Reson Imaging 8(4) (1990) 417–22.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=2392030&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

43. [43]. S.M. Smith,  M. Jenkinson,  M.W. Woolrich,  C.F. Beckmann,  T.E. Behrens,  H. Johansen-Berg,  P.R. Bannister,  M. De Luca,  I. Drobnjak,  D.E. Flitney,  R.K. Niazy,  J. Saunders,  J. Vickers,  Y. Zhang,  N. De Stefano,  J.M. Brady,  P.M. Matthews, Advances in functional and structural MR image analysis and implementation as FSL, NeuroImage 23 Suppl 1 (2004) S208–19.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.neuroimage.2004.07.051&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15501092&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000225374100020&link_type=ISI) 

44. [44]. E. Garyfallidis,  M. Brett,  B. Amirbekian,  A. Rokem,  S. van der Walt,  M. Descoteaux,  I. Nimmo-Smith,  C. Dipy, Dipy, a library for the analysis of diffusion MRI data, Front Neuroinform 8 (2014) 8.
    
    

45. [45]. J. Langley,  D.E. Huddleston,  B. Crosson,  D.D. Song,  S.A. Factor,  X. Hu, Multimodal assessment of nigrosomal degeneration in Parkinson’s disease, Parkinsonism & related disorders 80 (2020) 102–107.
    
    

46. [46]. J. Langley,  S. Hussain,  J.J. Flores,  I.J. Bennett,  X. Hu, Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta, Neurobiol Aging 87 (2020) 89–97.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

47. [47]. E. Makinen,  J. Joutsa,  J. Johansson,  M. Maki,  M. Seppanen,  V. Kaasinen, Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism, J Neural Transm (Vienna) 123(11) (2016) 1309–1318.
    
    

48. [48]. I.U. Isaias,  P. Trujillo,  P. Summers,  G. Marotta,  L. Mainardi,  G. Pezzoli,  L. Zecca,  A. Costa, Neuromelanin Imaging and Dopaminergic Loss in Parkinson’s Disease, Front Aging Neurosci 8 (2016) 196.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fnagi.2016.00196&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27597825&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F10%2F30%2F2022.10.26.22281257.atom) 

49. [49]. E. Biondetti,  M.D. Santin,  R. Valabregue,  G. Mangone,  R. Gaurav,  N. Pyatigorskaya,  M. Hutchison,  L. Yahia-Cherif,  N. Villain,  M.O. Habert,  I. Arnulf,  S. Leu-Semenescu,  P. Dodet,  M. Vila,  J.C. Corvol,  M. Vidailhet,  S. Lehericy, The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease, Brain 144(10) (2021) 3114–3125.
    
    

50. [50]. D.E. Huddleston,  J. Langley,  J. Sedlacik,  K. Boelmans,  S.A. Factor,  X.P. Hu, In vivo detection of lateral-ventral tier nigral degeneration in Parkinson’s disease, Hum Brain Mapp 38(5) (2017) 2627–2634.
    
    

51. [51]. J. Wang,  Z. Huang,  Y. Li,  F. Ye,  C. Wang,  Y. Zhang,  X. Cheng,  G. Fei,  K. Liu,  M. Zeng,  C. Zhong,  L. Jin, Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease, Parkinsonism & related disorders 58 (2019) 3–8.
    
    

52. [52]. R.M. Simoes,  A. Castro Caldas,  J. Grilo,  D. Correia,  C. Guerreiro,  P. Pita Lobo,  A. Valadas,  M. Fabbri,  L. Correia Guedes,  M. Coelho,  M.M. Rosa,  J.J. Ferreira,  S. Reimao, A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy, BMC Neurol 20(1) (2020) 432.
    
    

53. [53]. C. Ohtsuka,  M. Sasaki,  K. Konno,  K. Kato,  J. Takahashi,  F. Yamashita,  Y. Terayama, Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging, Parkinsonism & related disorders 20(7) (2014) 755–60.

 [1]: /embed/graphic-2.gif